• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Study On Drug Utilization And Assessment Of Stroke Risk Using Chads2 And Cha2ds2-Vasc Scoring In Elderly Patients With Non-Valvular Atrial Fibrillation
Stroke Risk Stratification in AF patients of can be done using CHADS2 (Congestive heart failure, Hypertension, Age ≥75, DM, prior Stroke/TIA [2 points] ); or CHA2DS2VASc2 (Congestive heart failure/left ventricular ejection fraction ≤35%, Hypertension, Age ≥75 [2 points], DM, prior Stroke/TIA/thromboembolism [2 points], Vascular disease, Age 65–74, Sex- female). Treatment options for Prevention of stroke includes Anti-coagulants (Vitamin K Antagonist-Warfarin, Acenocoumarol; and Newer Oral Anticoagulant- Dabigatran) and anti-platelets (Aspirin and Clopidogrel).
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: T. Raj, S. Bonthu, S.R. Mallayasamy Source Type: research

International study suggests combination therapy may prevent stroke in certain people
(NIH/National Institute of Neurological Disorders and Stroke) Results from an international clinical trial of more than 4880 participants, published in the New England Journal of Medicine, show that combining clopidogrel and aspirin following a small stroke or experiencing minor stroke symptoms decreases risk of a new stroke, heart attack or other ischemic event within 90 days. The combination therapy was also associated with an increase in major bleeding, although many of those episodes were non-fatal and did not occur in the brain.
Source: EurekAlert! - Medicine and Health - May 17, 2018 Category: International Medicine & Public Health Source Type: news

EE165 Cost-Effectiveness Analysis Model of Aspirin and Aspirin Combination Therapy in Acute Ischemic Stroke Patient in West Sumatera
Aspirin usage as monotherapy in acute ischemic stroke has been well-documented as the therapeutic option for early stroke management and recurrent stroke prevention. Recent studies have shown the potential of aspirin combination (dual antiplatelet therapy with clopidogrel) in effectively decreasing the possibility of recurrent stroke. Despite the promising clinical effectiveness, a cost-effectiveness model was built to compare these two options.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: N Fitria, F Putrizeti, YO Sari Source Type: research

Cost–Effectiveness of Clopidogrel-Aspirin Versus Aspirin Alone for Acute Tia and Minor Stroke
This study sought to estimate the cost-effectiveness of clopidogrel-aspirin regimen for acute TIA or minor stroke.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: Y. Pan, Y.L. Wang, G. Liu, K. Zhao, Y. Wang Source Type: research

Stroke prevention drug combo shows promise, study says
(University of Texas at Austin) If you've had a minor stroke or a transient ischemic stroke (TIA), taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days, according to new research published in The New England Journal of Medicine.
Source: EurekAlert! - Medicine and Health - May 16, 2018 Category: International Medicine & Public Health Source Type: news

Aspirin Versus Clopidogrel in Patients with Ischemic Stroke: a Cost and Effectiveness Comparison from Beijing Medical Insurance Database
To compare the cost and effectiveness of aspirin and clopidogrel in ischemic stroke(IS) patients from data of Beijing medical insurance database.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: L Wen, J Wu, L Yang Source Type: research

Aspirin Versus Clopidogrel in Prevention of Ischemic Stroke Recurrence: An Evaluation of Effectiveness and Safety from Beijing Medical Insurance Database
To evaluate the effectiveness and safety of aspirin and clopidrogel in prevention of ischemic stroke (IS) recurrence from data of Beijing medical insurance database.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: L Yang, L Wen, J Wu Source Type: research

Cost-Effectiveness of A Left Atrial Appendage Closure Device In Patients With Non-Valvular Atrial Fibrillation Unable or Unwilling to Tolerate Oral Anticoagulant Therapy In Italy And Spain
Approximately 18-20% of non-valvular atrial fibrillation (NVAF) patients are unable or unwilling to tolerate oral anticoagulant therapy (OAT), leaving them at risk of stroke. Left atrial appendage closure (LAAC) device offers an alternative stroke risk reduction strategy that enables the majority of patients to discontinue long-term systematic OAT. Acknowledging both potential improvements in health outcomes and additional upfront implantation costs of a LAAC device, this study considers the lifetime costs and benefits of LAAC compared to aspirin plus clopidogrel (A+C) in high-risk NVAF patients ineligible or unwilling to ...
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Amin, I Cruz González, V Reddy, D Holmes, S Berti, A Iñiguez Romo, L De Deppo, V Priest, M Simmonds, C Lee, M Wasserman, A Margonato Source Type: research

Cost-Effectiveness Analysis Of Ticagrelor In Treating Patients With Acute Coronary Syndrome In Hong Kong
This study aimed to evaluate the long-term cost-effectiveness of ticagrelor in ACS patients in Hong Kong (HK) from a public hospital’s perspective.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: D.B.C. Wu, B.S.C. Lee, K.K.C. Lee Source Type: research

Clopidogrel Versus Aspirin In Patients With Atherothrombosis: A Caprie-Based Economic Analysis In A Health Resource Limited Setting
To explore the cost-effectiveness of clopidogrel as secondary prevention in patients with a recent ischemic stroke (IS), or established peripheral arterial disease (PAD) compared with aspirin in China.
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: T. Li, M.B. Liu, H. Ben, Z.X. Xu, H. Zhong, B. Wu Source Type: research

Can Data Simulation Help Evaluate Hta Outcomes Over Time and Facilitate Early Decision-Making? a Case Study of Ticagrelor in Acute Coronary Syndrome in the Uk
In October 2011, the National Institute for Health and Care Excellence (NICE) recommended the use of ticagrelor in adult patients presenting with acute coronary syndrome (ACS) in England and Wales. The relative effectiveness and cost-effectiveness of ticagrelor compared to clopidogrel—the current standard of care in the NHS—were based on results from one large multicentre study including over 18,000 ACS patients. Patients were recruited from October 2006 through to July 2008 and primary trial data analysis, published in September 2009, demonstrated that ticagrelor significantly reduced the rate of death, myocardial inf...
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: P Dequen, NJ Cooper, K Abrams Source Type: research

Genetic test may improve post-stent treatment, outcome
(American Heart Association) A test for specific genetic mutations successfully informed blood-thinner treatment selection following stent placement to open clogged blood vessels, leading to significantly fewer complications. Genetic testing identified patients with specific mutations that render the widely used blood thinner clopidogrel ineffective. Patients with the genetic mutations who received alternative medications were much less likely to die or have a heart attack, stroke or other complications than patients with the mutations who received clopidogrel.
Source: EurekAlert! - Medicine and Health - April 3, 2018 Category: International Medicine & Public Health Source Type: news

Cilostazol-combo antiplatelet therapy reduced risk for recurrent stroke
(American Heart Association) The long-term combination of cilostazol with aspirin or clopidogrel resulted in fewer recurrent strokes than with aspirin or clopidogrel alone in high-risk patients.
Source: EurekAlert! - Medicine and Health - February 6, 2019 Category: International Medicine & Public Health Source Type: news

Stopping aspirin three months after stenting does not increase risk of death
(American College of Cardiology) Patients who stopped taking aspirin three months after receiving a stent to open the heart's arteries but continued taking a P2Y12 inhibitor -- clopidogrel, prasugrel or ticagrelor -- did not experience higher rates of death from any cause, heart attack or stroke after a year compared with those receiving standard therapy, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. Furthermore, patients who stopped taking aspirin after three months had a significantly lower rate of bleeding.
Source: EurekAlert! - Medicine and Health - March 18, 2019 Category: International Medicine & Public Health Source Type: news